Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease

Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease

(2021) Yu Xu et al.   Hepatology International

Celastrol in metabolic diseases: Progress and application prospects

(2021) Shaohua Xu et al.   PHARMACOLOGICAL RESEARCH

Nanotechnology-Based Celastrol Formulations and Their Therapeutic Applications

(2021) Pushkaraj Rajendra Wagh et al.   Frontiers in Pharmacology

Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine

(2020) Tingting Shi et al.   Evidence-based Complementary and Alternative Medicine

Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma

(2020) Chan-juan Zhang et al.   ACTA PHARMACOLOGICA SINICA

Modulation of Lipid Metabolism by Celastrol

(2019) Ting Zhang et al.   JOURNAL OF PROTEOME RESEARCH

Celastrol-loaded PEG-PCL nanomicelles ameliorate inflammation, lipid accumulation, insulin resistance and gastrointestinal injury in diet-induced obese mice

(2019) Jia Zhao et al.   JOURNAL OF CONTROLLED RELEASE

Endoplasmic Reticulum stress signaling and the pathogenesis of Non-Alcoholic Fatty Liver Disease

(2018) Cynthia Lebeaupin et al.   JOURNAL OF HEPATOLOGY

Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future

(2018) Ana Ruth Araújo et al.   LIVER INTERNATIONAL

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

AMPK Activation Reduces Hepatic Lipid Content by Increasing Fat Oxidation In Vivo

(2018) Marc Foretz et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration

(2018) Yike Huang et al.   International Journal of Nanomedicine

Asialoglycoprotein receptor-targeted liposomes loaded with a norcantharimide derivative for hepatocyte-selective targeting

(2017) Xiaolin Liu et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance

(2017) Daniel Garcia et al.   MOLECULAR CELL

Fatty liver disease: turning the tide

(2017) Liam Drew   NATURE

Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1

(2017) Yinliang Zhang et al.   Molecular Metabolism

Cascade regulation of PPARγ2 and C/EBPα signaling pathways by celastrol impairs adipocyte differentiation and stimulates lipolysis in 3T3-L1 adipocytes

(2016) Seung Kug Choi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

NAFLD and diabetes mellitus

(2016) Herbert Tilg et al.   Nature Reviews Gastroenterology & Hepatology

Plant-derived triterpene celastrol ameliorates oxygen glucose deprivation-induced disruption of endothelial barrier assembly via inducing tight junction proteins

(2016) Dan Luo et al.   PHYTOMEDICINE

Treatment of Obesity with Celastrol

(2015) Junli Liu et al.   CELL

Celastrol Protects against Obesity and Metabolic Dysfunction through Activation of a HSF1-PGC1α Transcriptional Axis

(2015) Xinran Ma et al.   Cell Metabolism

Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications

(2015) Anisha A. D'Souza et al.   JOURNAL OF CONTROLLED RELEASE

Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

(2015) Mohamed Asrih et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Celastrol identified as a leptin sensitizer and potential novel treatment for obesity

(2015) Claire Greenhill   Nature Reviews Endocrinology

Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism

(2014) Chaoyun Wang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous?

(2014) Chunlei Li et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

From NAFLD to NASH to cirrhosis—new insights into disease mechanisms

(2013) Alexander Wree et al.   Nature Reviews Gastroenterology & Hepatology

Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice

(2013) Jung Eun Kim et al.   PLoS One

Albumin-based nanoparticles as potential controlled release drug delivery systems

(2011) Ahmed O. Elzoghby et al.   JOURNAL OF CONTROLLED RELEASE

In Vitro Evaluation of Potential Hepatotoxicity Induced by Drugs

(2010) M.J. Gomez-Lechon et al.   CURRENT PHARMACEUTICAL DESIGN

Animal models of nonalcoholic fatty liver disease

(2010) Lionel Hebbard et al.   Nature Reviews Gastroenterology & Hepatology

Pathogenesis of non-alcoholic fatty liver disease

(2009) J. K. Dowman et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase

(2008) Xiuyun Hou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY